ArticleCureus2025
Managing Commissural Mitral Valve Regurgitation Following Transcatheter Mitral Valve Repair Using the Amplatzer Occluder Device.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitral regurgitation (MR) is a common valvular abnormality in patients in the Western world. Treatment options include surgery and edge-to-edge repair of the mitral valve leaflets using the MitraClip device. However, MR may recur, and MitraClip can be unsuccessful, posing a challenging management dilemma. We present a case involving a 74-year-old male patient who originally presented due to severe symptomatic MR. The patient originally underwent successful intervention with a MitraClip. However, the patient reported recurrent dyspnea with little effort approximately six months after the index procedure. A repeat 3D transesophageal echocardiogram revealed severe recurrent MR at the medial commissure with an eccentric jet, similar to findings from prior studies. Due to the medial location of the defect, limited space to steer an additional clip, and high surgical risk, the patient was not a suitable candidate for surgical intervention or repeat MitraClip (Abbott Vascular, Santa Clara, CA) placement. The severe recurrent commissural MR was successfully managed using an Amplatzer Patent Foramen Ovale Occluder device (St. Jude Medical, Minneapolis, MN) in an off-label fashion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.